Carl Zeiss Meditec (ETR:AFX) target price raised to 36.00EUR, reported today by Joh. Berenberg Gossler & Co. KG
- Updated: September 19, 2016
Stating a possible upside of 0.04%, Joh. Berenberg Gossler & Co. KG raised the price target of Carl Zeiss Meditec (ETR:AFX) to 36EUR.
On 9/19/2016, Joh. Berenberg Gossler & Co. KG released a statement about Carl Zeiss Meditec(ETR:AFX) raised the target price from 0.00EUR to 36.00EUR that indicated a possible upside of 0.04%.
Only yesterday Carl Zeiss Meditec (ETR:AFX) traded 0.00% even at 34.45EUR. AFX’s 50-day average is 0.00EUR and its two hundred day average is 0.00EUR. With the last stock price up 0.00% from the 200-day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same period. Trading volume held steady, with 0 shares of AFX changing hands on par with the typical 0 shares..
Carl Zeiss Meditec has a 52 week low of 0.00EUR and a one-year high of 0.00EUR and has a total market value of 0.0 EUR.
Brief Synopsis About Carl Zeiss Meditec (ETR:AFX)
Carl Zeiss Meditec AG is a Germany-based medical technology solutions supplier. The Company operates, along with its subsidiaries, in two business areas: Ophthalmology and Microsurgery. The Ophthalmology business area is subdivided into two business units: the Ophthalmology systems unit covers a range of laser and diagnostic systems for ophthalmology, and the Surgical Ophthalmology unit combines the Company’s activities in the field of ophthalmic implants and disposables. The Microsurgery business area offers surgical microscopes and visualization solutions for ear, nose and throat surgery, or neurosurgery. Its microsurgery products are mainly used as supporting equipment for the removal of tumors, as well as the treatment of vascular diseases and functional disorders. In January 2014, it acquired Optronik Optik ve Elektronik Cihazlar Ticaret ve Sanayi AS, a wholesaler of ophthalmology products, as well as a 100% stake in Aaren Scientific Inc, and a producer of intraocular lenses.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.